Richard Pops Net Worth

The estimated Net Worth of Richard F Pops is at least $19.8 Milion dollars as of 17 May 2024. Mr. Pops owns over 4,199 units of Alkermes plc stock worth over $895,701 and over the last 22 years he sold ALKS stock worth over $4,226,531. In addition, he makes $14,637,100 as Chairman of the Board a Chief Executive Officer at Alkermes plc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Pops ALKS stock SEC Form 4 insiders trading

Richard has made over 115 trades of the Alkermes plc stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 4,199 units of ALKS stock worth $111,567 on 17 May 2024.

The largest trade he's ever made was exercising 450,000 units of Alkermes plc stock on 5 May 2022 worth over $7,447,500. On average, Richard trades about 30,635 units every 27 days since 2003. As of 17 May 2024 he still owns at least 33,711 units of Alkermes plc stock.

You can see the complete history of Mr. Pops stock trades at the bottom of the page.

Richard Pops biography

Richard F. Pops is Chairman of the Board, Chief Executive Officer of the Company. Prior to assuming his current positions, Mr. Pops served as Chief Executive Officer of Alkermes, Inc. from February 1991 to April 2007 and as Chief Executive Officer and President from September 2009 to September 2011. Mr. Pops currently serves on the boards of directors of Neurocrine Biosciences, Inc., a publicly-traded biotechnology company, the BIO and PhRMA. Consistent with our revised “overboarding” policy and the more stringent “overboarding” policies of certain of our shareholders, Mr. Pops resigned from the board of directors of Epizyme, Inc., a publicly-traded biotechnology company, effective upon the earlier of Epizyme’s appointment of a replacement director or October 31, 2020. He previously served on the boards of directors of Acceleron Pharma, Inc., a publicly-traded biotechnology company, from 2004 to December 2019, and the National Health Council, a nonprofit organization, from 2016 to December 2019. Mr. Pops also previously served on the advisory board of Polaris Venture Partners and as a member of the Harvard Medical School Board of Fellows through June 2012.

What is the salary of Richard Pops?

As the Chairman of the Board a Chief Executive Officer of Alkermes plc, the total compensation of Richard Pops at Alkermes plc is $14,637,100. There are no executives at Alkermes plc getting paid more.

How old is Richard Pops?

Richard Pops is 58, he's been the Chairman of the Board a Chief Executive Officer of Alkermes plc since 2011. There are 13 older and 9 younger executives at Alkermes plc. The oldest executive at Alkermes plc is Dr. Floyd E. Bloom M.D., 84, who is the Founder.

What's Richard Pops's mailing address?

Richard's mailing address filed with the SEC is 12780, El Camino Real, San Diego, San Diego County, California, 92014, United States.

Insiders trading at Alkermes plc

Over the last 13 years, insiders at Alkermes plc have traded over $407,046,771 worth of Alkermes plc stock and bought 86,119 units worth $2,034,840 . The most active insiders traders include Corp Plc Elan Science Three..., Richard F Pops a James M Frates. On average, Alkermes plc executives and independent directors trade stock every 5 days with the average trade being worth of $1,083,232. The most recent stock trade was executed by David Joseph Gaffin on 3 August 2024, trading 2,014 units of ALKS stock currently worth $53,512.

What does Alkermes plc do?

alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (cns) diseases. the company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. headquartered in dublin, ireland, alkermes plc has an r&d center in waltham, massachusetts; a research and manufacturing facility in athlone, ireland; and a manufacturing facility in wilmington, ohio. for more information, please visit alkermes’ website at www.alkermes.com.

Complete history of Mr. Pops stock trades at Acceleron Pharma Inc, Alkermes plc, Epizyme Inc a Neurocrine Biosciences

Alkermes plc executives and stock owners

Alkermes plc executives and other stock owners filed with the SEC include:

• Richard Pops,
  Chairman of the Board, Chief Executive Officer
• Craig Hopkinson,
  Executive Vice President, Research and Development and Chief Medical Officer
• David Gaffin,
  Senior Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
• James Frates,
  Chief Financial Officer, Senior Vice President
• Michael Landine,
  Senior Vice President - Corporate Development, Chief Risk Officer
• Richard F. Pops,
  Chairman & CEO
• Dr. Craig C. Hopkinson,
  Exec. VP of R&D and Chief Medical Officer
• David Joseph Gaffin,
  Sr. VP, Chief Legal Officer, Chief Compliance Officer & Sec.
• Frank Wilson,
  Independent Director
• Richard Gaynor,
  Independent Director
• Michael J. Landine,
  Sr. VP of Corp. Devel. & Chief Risk Officer
• Paul Mitchell,
  Independent Director
• Robert Breyer,
  Independent Director
• David Anstice,
  Lead Independent Director
• Nancy Snyderman,
  Independent Director
• Wendy Dixon,
  Independent Director
• Nancy Wysenski,
  Independent Director
• Shane Cooke,
  Director
• Iain Brown,
  Senior Vice President - Finance, Chief Accounting Officer
• Peter Norman,
  Sr. VP of Policy & Gov. Relations
• Iain Michael Brown,
  Sr. VP & CFO
• Dr. Floyd E. Bloom M.D.,
  Founder
• Stephen Schiavo,
  Sr. VP of HR
• Eva Stroynowski,
  VP of Product & R&D Communications, Public Affairs
• Sandra Coombs,
  Co-Head of Investor Relations
• Blair C. Jackson,
  Exec. VP & COO
• Dr. Floyd E. Bloom,
  Founder
• Floyd E Bloom,
  Director
• Elliot Ehrich,
  SVP, R&D & CMO, Alkermes, Inc.
• Mark Stejbach,
  Chief Commercial Officer
• James A. Jr. Robinson,
  President & COO,Alkermes, Inc.
• Nancy Lurker,
  Director
• Rebecca Peterson,
  SVP, Corporate Communications
• Geraldine Henwood,
  Director
• Kathryn L Biberstein,
  SVP, GC, Secretary, Alks, Inc.
• Gordon G Pugh,
  SVP, COO & CRO, Alkermes, Inc.
• James L Botkin,
  SVP, Alkermes Gainesville LLC
• Mark B Skaletsky,
  Director
• Corp Plc Elan Science Three...,
  
• Christian Todd Nichols,
  SVP, Chief Commercial Officer
• Brian P Mckeon,
  Director
• David Angelo Jr. Daglio,
  Director
• Blair Curtis Jackson,
  EVP, Chief Operating Officer
• Emily Peterson Alva,
  Director
• Cato T Laurencin,
  Director
• Christopher I Wright,
  Director
• Samuel Joseph Parisi,
  VP, Finance (Interim PAO)